Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
CELG's Cash-to-Debt is ranked lower than
83% of the 1046 Companies
in the Global Biotechnology industry.

( Industry Median: 55.72 vs. CELG: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 3.39 Max: No Debt
Current: 0.76
0.06
No Debt
Equity-to-Asset 0.23
CELG's Equity-to-Asset is ranked lower than
87% of the 767 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.75 Max: 0.97
Current: 0.23
-0.3
0.97
Debt-to-Equity 2.29
CELG's Debt-to-Equity is ranked lower than
94% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 0.26 vs. CELG: 2.29 )
Ranked among companies with meaningful Debt-to-Equity only.
CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.43 Max: 2.39
Current: 2.29
-4.28
2.39
Debt-to-EBITDA 3.01
CELG's Debt-to-EBITDA is ranked lower than
65% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.94 vs. CELG: 3.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CELG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 5.18
Current: 3.01
0.97
5.18
Interest Coverage 9.01
CELG's Interest Coverage is ranked lower than
86% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 9.01 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.33  Med: 19.75 Max: 428.04
Current: 9.01
6.33
428.04
Piotroski F-Score: 8
Altman Z-Score: 3.86
Beneish M-Score: -2.75
WACC vs ROIC
8.89%
26.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 36.17
CELG's Operating Margin % is ranked higher than
94% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -105.96 vs. CELG: 36.17 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: -64.94  Med: 28.99 Max: 36.2
Current: 36.17
-64.94
36.2
Net Margin % 22.38
CELG's Net Margin % is ranked higher than
89% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -92.13 vs. CELG: 22.38 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.45 Max: 28.88
Current: 22.38
-68.02
28.88
ROE % 36.86
CELG's ROE % is ranked higher than
96% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: -39.05 vs. CELG: 36.86 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 25.73 Max: 43.49
Current: 36.86
-48.42
43.49
ROA % 9.76
CELG's ROA % is ranked higher than
91% of the 1052 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. CELG: 9.76 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 9.76
-38.07
15.8
ROC (Joel Greenblatt) % 360.99
CELG's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1014 Companies
in the Global Biotechnology industry.

( Industry Median: -432.52 vs. CELG: 360.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 396.39
Current: 360.99
-421.4
396.39
3-Year Revenue Growth Rate 20.60
CELG's 3-Year Revenue Growth Rate is ranked higher than
73% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CELG: 20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -42.8  Med: 31 Max: 241.3
Current: 20.6
-42.8
241.3
3-Year EBITDA Growth Rate 24.10
CELG's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CELG: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -34  Med: 19.85 Max: 295.8
Current: 24.1
-34
295.8
3-Year EPS without NRI Growth Rate 15.10
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
69% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. CELG: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.8  Med: 15.25 Max: 109.7
Current: 15.1
-60.8
109.7
GuruFocus has detected 1 Warning Sign with Celgene Corp CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

CELG Guru Trades in Q1 2017

Jeremy Grantham 1,900 sh (New)
Stanley Druckenmiller 82,400 sh (New)
Ray Dalio 43,412 sh (New)
John Burbank 20,710 sh (New)
David Rolfe 192,000 sh (New)
Signature Select Canadian Fund 51,450 sh (+48.27%)
Joel Greenblatt 158,126 sh (+31.79%)
Pioneer Investments 5,231,139 sh (+15.72%)
Mario Gabelli 12,709 sh (+12.08%)
Ronald Muhlenkamp 3,000 sh (unchged)
Murray Stahl 8,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
George Soros Sold Out
Ronald Muhlenkamp 72,493 sh (-0.27%)
Ken Fisher 201,869 sh (-0.80%)
Julian Robertson 286,340 sh (-4.15%)
Paul Tudor Jones 1,900 sh (-9.52%)
Steven Cohen 330,000 sh (-48.99%)
Jim Simons 132,138 sh (-82.41%)
» More
Q2 2017

CELG Guru Trades in Q2 2017

Caxton Associates 3,600 sh (New)
Lee Ainslie 19,150 sh (New)
Jim Simons 1,170,638 sh (+785.92%)
David Rolfe 799,402 sh (+316.36%)
Jeremy Grantham 3,000 sh (+57.89%)
Ken Fisher 263,929 sh (+30.74%)
Joel Greenblatt 168,817 sh (+6.76%)
Murray Stahl 8,155 sh (+1.94%)
Ronald Muhlenkamp 3,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 444,921 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
Ronald Muhlenkamp 72,418 sh (-0.10%)
Pioneer Investments 5,193,810 sh (-0.71%)
Julian Robertson 283,240 sh (-1.08%)
Ray Dalio 40,801 sh (-6.01%)
Mario Gabelli 10,529 sh (-17.15%)
» More
Q3 2017

CELG Guru Trades in Q3 2017

Frank Sands 4,130 sh (New)
Stanley Druckenmiller 188,100 sh (New)
Steven Cohen 77,242 sh (New)
Ray Dalio 85,286 sh (+109.03%)
Joel Greenblatt 195,353 sh (+15.72%)
Signature Select Canadian Fund 51,850 sh (+0.78%)
Ken Fisher 265,695 sh (+0.67%)
Ronald Muhlenkamp 3,000 sh (unchged)
Lee Ainslie Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 71,455 sh (-1.33%)
Mario Gabelli 10,250 sh (-2.65%)
Murray Stahl 7,939 sh (-2.65%)
Jeremy Grantham 2,700 sh (-10.00%)
David Rolfe 676,776 sh (-15.34%)
Julian Robertson 219,540 sh (-22.49%)
Pioneer Investments 2,522,142 sh (-51.44%)
Jim Simons 410,238 sh (-64.96%)
Eaton Vance Worldwide Health Sciences Fund 409,520 sh (-7.96%)
» More
Q4 2017

CELG Guru Trades in Q4 2017

Richard Pzena 2,371 sh (New)
First Pacific Advisors 4,175 sh (New)
Tom Russo 500 sh (New)
Frank Sands 43,919 sh (+963.41%)
Ray Dalio 290,776 sh (+240.94%)
Steven Cohen 200,000 sh (+158.93%)
Jim Simons 796,200 sh (+94.08%)
David Rolfe 962,318 sh (+42.19%)
Joel Greenblatt 200,934 sh (+2.86%)
Ronald Muhlenkamp 3,000 sh (unchged)
Julian Robertson Sold Out
Jeremy Grantham Sold Out
Stanley Druckenmiller Sold Out
Murray Stahl 7,900 sh (-0.49%)
Ronald Muhlenkamp 70,101 sh (-1.89%)
Ken Fisher 231,106 sh (-13.02%)
Mario Gabelli 3,400 sh (-66.83%)
Pioneer Investments 814,675 sh (-67.70%)
Eaton Vance Worldwide Health Sciences Fund 386,544 sh (-5.61%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-12-31 Reduce -13.02%0.01%$98.17 - $146.52 $ 93.89-17%231,106
Joel Greenblatt 2017-12-31 Add 2.86%0.01%$98.17 - $146.52 $ 93.89-17%200,934
Ronald Muhlenkamp 2017-12-31 Reduce -1.89%0.06%$98.17 - $146.52 $ 93.89-17%70,101
Mario Gabelli 2017-12-31 Reduce -66.83%0.01%$98.17 - $146.52 $ 93.89-17%3,400
Richard Pzena 2017-12-31 New Buy$98.17 - $146.52 $ 93.89-17%2,371
Julian Robertson 2017-12-31 Sold Out 5.79%$98.17 - $146.52 $ 93.89-17%0
Ken Fisher 2017-09-30 Add 0.67%$127.43 - $144.94 $ 93.89-31%265,695
Julian Robertson 2017-09-30 Reduce -22.49%1.63%$127.43 - $144.94 $ 93.89-31%219,540
Joel Greenblatt 2017-09-30 Add 15.72%0.06%$127.43 - $144.94 $ 93.89-31%195,353
Ronald Muhlenkamp 2017-09-30 Reduce -1.33%0.04%$127.43 - $144.94 $ 93.89-31%71,455
Mario Gabelli 2017-09-30 Reduce -2.65%$127.43 - $144.94 $ 93.89-31%10,250
Julian Robertson 2017-06-30 Reduce -1.08%0.07%$114.41 - $134.31 $ 93.89-23%283,240
Ken Fisher 2017-06-30 Add 30.74%0.01%$114.41 - $134.31 $ 93.89-23%263,929
Joel Greenblatt 2017-06-30 Add 6.76%0.02%$114.41 - $134.31 $ 93.89-23%168,817
Ronald Muhlenkamp 2017-06-30 Reduce -0.10%$114.41 - $134.31 $ 93.89-23%72,418
Mario Gabelli 2017-06-30 Reduce -17.15%$114.41 - $134.31 $ 93.89-23%10,529
Julian Robertson 2017-03-31 Reduce -4.15%0.26%$111.53 - $126.88 $ 93.89-22%286,340
Ken Fisher 2017-03-31 Reduce -0.80%$111.53 - $126.88 $ 93.89-22%201,869
Joel Greenblatt 2017-03-31 Add 31.79%0.06%$111.53 - $126.88 $ 93.89-22%158,126
Ronald Muhlenkamp 2017-03-31 Reduce -0.27%0.01%$111.53 - $126.88 $ 93.89-22%72,493
Mario Gabelli 2017-03-31 Add 12.08%$111.53 - $126.88 $ 93.89-22%12,709
George Soros 2017-03-31 Sold Out 0.01%$111.53 - $126.88 $ 93.89-22%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, NAS:GILD, ASX:CSL, NAS:VRTX, LSE:SHP, NAS:REGN, OCSE:NOVO B, XKRX:068270, NAS:ALXN, XKRX:207940, NAS:AMGN, NAS:INCY, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, OCSE:NZYM B, SZSE:002252, HKSE:01177, NAS:ALNY, NAS:NKTR » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Guru Investment Theses on Celgene Corp

David Rolfe Comments on Celgene - Jan 12, 2018

Celgene (NASDAQ:CELG)



Celgene was a top detractor to performance due to a couple negative news events released during the quarter. The company announced they would discontinue a phase III trial for their drug GED-0301 in Crohn's disease (CD) and an extension trial, following a recommendation of the Data Monitoring Committee. They also decided that another phase 1 trial for Crohn's disease would not be initiated. While a phase II trial with GED-0301 in ulcerative colitis is still ongoing, the Company is currently awaiting review of data to determine their next steps for this indication. In the absence of any information on whether the trial failure was due to something specific to CD or the drug itself, it is currently assumed to be a high-risk program for that indication. This study was deemed a high risk/low-probability study, especially when compared to other IBD drugs. However, its success could have been a blockbuster Inflammation & Immunology (I&I) asset for the company, making its failure a disappointing loss.



In addition to these trial failures, during the third quarter earnings release, management brought down 2020 guidance, partially due to the discontinuation of GED-0301 program in CD. While sales were only modest in their 2020 model, management did forecast multibillion dollar peak sales potential for the drug. The largest impact to 2020 guidance, however, was weak performance of their existing drug Otezla, which experienced headwinds due to slowing growth and increased competition in the psoriatic arthritis and psoriasis markets. The updated guidance takes into account GED-0301, the market dynamics impacting Otezla, as well as reassesses the opportunities and risks associated with the remaining phase III studies expected to read out by the end of 2018. We believe management took a conservative stance with their update and yet the resulting guide maintains more than +14% revenue growth and nearly +20% earnings growth on a compounded annual basis through 2020.



We realize there will be phase III failures; and with each failure comes the potential for more risk and less growth. We reiterate that the Company has a very broad pipeline, with 12 phase 1 studies set to read out between now and the end of this year, making setbacks like these more manageable in the longer term. Celgene has substantially more phase III assets than any other biotech company. Several of these pipeline assets are not incorporated in the current 2020 guidance, as they read out at a date when any sales potential will contribute at future dates. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s fourth quarter 2017 shareholder commentary.

Check out David Rolfe latest stock trades

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

David Rolfe Axes TreeHouse Foods, Exxon Mobil in 4th Quarter Wedgewood reports quarterly portfolio
David Rolfe (Trades, Portfolio), chief investment officer at Wedgewood Partners, released his fourth-quarter portfolio last week, disclosing he exited his positions in TreeHouse Foods Inc. (NYSE:THS) and Exxon Mobil Corp. (NYSE:XOM). Read more...
Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration
Tiger Management’s Top 3 Sells Outweigh Top 3 Buys in 4th Quarter Firm discloses quarterly portfolio
Tiger Management, founded by legendary hedge fund manager Julian Robertson (Trades, Portfolio), disclosed Wednesday its top three buys and sells for the quarter ending Dec. 31, 2017. The firm divested 88% of its stake in Alibaba Group Holding Ltd. (NYSE:BABA) and its entire stake in two other companies: Celgene Corp. (NASDAQ:CELG) and Boston Scientific Corp. (NYSE:BSX). With the proceeds from these trades, the firm initiated positions in eBay Inc. (NASDAQ:EBAY), IQVIA Holdings Inc. (NYSE:IQV) and Comcast Corp. (NASDAQ:CMCSA). Read more...
The Quest to Develop the First Alzheimer’s Disease Treatment The reasons Pfizer recently decided to stop pursuing neurological disease research and what to look forward to in the near future regarding Alzheimer's disease treatments
The excitement Read more...
Richard Pzena’s Top 5 New Buys of the 4th Quarter Guru reports quarterly portfolio
Pzena Investment Management leader Richard Pzena (Trades, Portfolio) released his fourth-quarter portfolio last week, disclosing he opened nine new positions. Read more...
Stocks That Fell to 3-Year Lows in the Week of Feb. 9 Anheuser-Busch InBev SA/NV (BUD), CVS Health Corp. (CVS), Celgene Corp. (CELG), and Allergan PLC. (AGN) have declined to their respective three-year lows
Anheuser-Busch InBev SA/NV (NYSE:BUD), CVS Health Corp. (NYSE:CVS), Celgene Corp. (NASDAQ:CELG), and Allergan PLC. (NYSE:AGN) have declined to their three-year lows. Read more...
Weekly Top Insider Buys Highlight for the Week of Feb. 9 The largest Insider Buys this week were for AT&T Inc. (T), Celgene Corp. (CELG), Delta Air Lines Inc. (DAL) and Aon PLC. (AON)
The largest Insider Buys this week were for AT&T Inc. (NYSE:T), Celgene Corp. (NASDAQ:CELG), Delta Air Lines Inc. (NYSE:DAL) and Aon PLC. (NYSE:AON). Read more...
Investor Expectations to Drive Momentum within Connecticut Water Service, Datawatch, Cadiz, Celgene, Texas Instruments, and Newfield Exploration — Discovering Underlying Factors of Influence
WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition
Celgene Acquires Company Investigating Cancer Warfare Drug Juno Therapeutics stock jumped 27% after $9 billion deal was announced
One of the largest biopharmaceutical players in the world, Celgene Corp. (NASDAQ:CELG), has announced a $9 billion deal to acquire Juno Therapeutics Inc. (NASDAQ:JUNO) as part of its plans to ramp up development of experimental blood-cancer drugs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 26.23
CELG's PE Ratio is ranked higher than
55% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 28.26 vs. CELG: 26.23 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 17.92  Med: 42.39 Max: 230.5
Current: 26.23
17.92
230.5
Forward PE Ratio 10.80
CELG's Forward PE Ratio is ranked higher than
91% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 22.08 vs. CELG: 10.80 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.23
CELG's PE Ratio without NRI is ranked higher than
56% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. CELG: 26.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.82  Med: 42.39 Max: 215.13
Current: 26.23
17.82
215.13
Price-to-Owner-Earnings 18.52
CELG's Price-to-Owner-Earnings is ranked higher than
73% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 35.22 vs. CELG: 18.52 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.44  Med: 37.41 Max: 922
Current: 18.52
15.44
922
PB Ratio 10.68
CELG's PB Ratio is ranked lower than
80% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CELG: 10.68 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.27 Max: 18.15
Current: 10.68
4.02
18.15
PS Ratio 5.84
CELG's PS Ratio is ranked higher than
66% of the 731 Companies
in the Global Biotechnology industry.

( Industry Median: 11.11 vs. CELG: 5.84 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 5.37  Med: 9.14 Max: 25.21
Current: 5.84
5.37
25.21
Price-to-Free-Cash-Flow 15.26
CELG's Price-to-Free-Cash-Flow is ranked higher than
73% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 30.41 vs. CELG: 15.26 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 30.88 Max: 336.15
Current: 15.26
14.87
336.15
Price-to-Operating-Cash-Flow 14.45
CELG's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 26.94 vs. CELG: 14.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.85  Med: 27.96 Max: 187.62
Current: 14.45
13.85
187.62
EV-to-EBIT 15.51
CELG's EV-to-EBIT is ranked higher than
66% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.83 vs. CELG: 15.51 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.6  Med: 31.45 Max: 90.4
Current: 15.51
-28.6
90.4
EV-to-EBITDA 14.12
CELG's EV-to-EBITDA is ranked higher than
65% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 20.69 vs. CELG: 14.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.4  Med: 26.7 Max: 83
Current: 14.12
-31.4
83
EV-to-Revenue 5.73
CELG's EV-to-Revenue is ranked higher than
68% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 12.21 vs. CELG: 5.73 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.1  Med: 9.1 Max: 25.7
Current: 5.73
5.1
25.7
PEG Ratio 1.22
CELG's PEG Ratio is ranked higher than
64% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. CELG: 1.22 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.32 Max: 3.26
Current: 1.22
1.22
3.26
Shiller PE Ratio 60.19
CELG's Shiller PE Ratio is ranked lower than
63% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. CELG: 60.19 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 59.3  Med: 135.19 Max: 3211
Current: 60.19
59.3
3211
Current Ratio 4.99
CELG's Current Ratio is ranked higher than
57% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CELG: 4.99 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.66 Max: 29.92
Current: 4.99
1.35
29.92
Quick Ratio 4.80
CELG's Quick Ratio is ranked higher than
58% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.86 vs. CELG: 4.80 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.61 Max: 29.92
Current: 4.8
1.13
29.92
Days Inventory 414.56
CELG's Days Inventory is ranked lower than
92% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. CELG: 414.56 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 105.47  Med: 297.82 Max: 414.56
Current: 414.56
105.47
414.56
Days Sales Outstanding 53.94
CELG's Days Sales Outstanding is ranked higher than
59% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 65.03 vs. CELG: 53.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.55  Med: 57.78 Max: 71.27
Current: 53.94
50.55
71.27
Days Payable 241.49
CELG's Days Payable is ranked higher than
86% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 59.19 vs. CELG: 241.49 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 172.59 Max: 241.49
Current: 241.49
61.81
241.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.50
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CELG: 0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.3 Max: 4.5
Current: 0.5
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.49
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.39 vs. CELG: 1.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.49  Med: 4.6 Max: 55
Current: 1.49
1.49
55
Price-to-Median-PS-Value 0.64
CELG's Price-to-Median-PS-Value is ranked higher than
71% of the 629 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CELG: 0.64 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.87 Max: 15.33
Current: 0.64
0.64
15.33
Price-to-Peter-Lynch-Fair-Value 1.27
CELG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
63% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 1.51 vs. CELG: 1.27 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.46  Med: 1.71 Max: 5.1
Current: 1.27
0.46
5.1
Earnings Yield (Greenblatt) % 6.45
CELG's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -7.37 vs. CELG: 6.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 2.9 Max: 6.7
Current: 6.45
-7.5
6.7
Forward Rate of Return (Yacktman) % 24.82
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
74% of the 134 Companies
in the Global Biotechnology industry.

( Industry Median: 11.90 vs. CELG: 24.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.1  Med: 2.4 Max: 34.8
Current: 24.82
0.1
34.8

More Statistics

Revenue (TTM) (Mil) $12,998.00
EPS (TTM) $ 3.58
Beta1.22
Short Percentage of Float1.85%
52-Week Range $88.32 - 147.17
Shares Outstanding (Mil)752.18

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 14,911 17,552 20,338
EBIT (Mil $) 7,893 10,374 11,425
EBITDA (Mil $) 8,374 10,869 11,893
EPS ($) 8.46 10.29 12.26
EPS without NRI ($) 8.46 10.29 12.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
18.49%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}